Wechselwirkungen · Epclusa
Epclusa 200 mg/50 mg coated granules in sachet Epclusa 150 mg/37.5 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 42–43
HOS-136194 · Präparat HOS-097846
42 Medicinal product by Effects on medicinal product levels. therapeutic areas/Possible Mean ratio (90% confidence interval)a,b Recommendation concerning Mechanism of Interaction Active Cmax AUC Cmin co-administration with Epclusa Emtricitabine/ rilpivirine/ Rilpivirine ↔ ↔ ↔ No dose adjustment of Epclusa or tenofovir disoproxil Sofosbuvir ↔ ↔ emtricitabine/ rilpivirine/ tenofovir fumarate Velpatasvir ↔ ↔ ↔ disoproxil fumarate is required. (200/ 25/ 300 mg once daily)/ sofosbuvir/ velpatasvir (400/ 100 mg once daily)c, d HIV ANTIVIRAL AGENTS: HIV PROTEASE INHIBITORS Atazanavir boosted with Atazanavir ↔ ↔ ↑ No dose adjustment of Epclusa, ritonavir (300/ 100 mg once 1.4 atazanavir (ritonavir boosted) or daily) + emtricitabine/ (1.2, emtricitabine/ tenofovir disoproxil tenofovir disoproxil 1.6) fumarate is required. fumarate (200/ 300 mg once Ritonavir ↔ ↑ daily)/ sofosbuvir/ 1.3 velpatasvir (400/ 100 mg (1.5, once daily)c, d 1.4) Sofosbuvir ↔ ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) protease (HOS-085623) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) rilpivirine (HOS-088090) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage b9fcd88c28ec6a6fa24ae1785134845d4a30a8adb19d618b90829e9cc02a53c5 · Zeichen 18300–19730 im Abschnitt